LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

NVO

126.83

-0.63%↓

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

Home・Stock List・ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc

Closed

Sector Healthcare

19.16 3.23

Buy Sell

Overview

Share price change

24h

Current

Min

18.53

Max

19.2

Key metrics
By Trading Economics
Income	-29M 17M
Sales	-25M 206M
EPS	0.1
Profit margin	8.044
Employees	597
EBITDA	-16M 21M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+50.3 upside

Dividends
By Dow Jones
Next Earnings	6 Aug 2024

Market Stats
By TradingEconomics
Market Cap	354M 3B
Previous open	15.93
Previous close	19.16

News Sentiment

By Acuity

100%

349 / 369 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

18.15 / 18.62 Support & Resistance

ACADIA Pharmaceuticals Inc Chart

Related News

25 Jul 2024, 20:16 UTC

Earnings

Norfolk Southern Grows 2Q Profit, Seeks to Leave Behind Derailment Tailwinds

25 Jul 2024, 22:57 UTC

Earnings

Minas Buenaventura 2Q Net $74.4M >BVN

25 Jul 2024, 22:10 UTC

Earnings

Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25 Jul 2024, 21:59 UTC

Market Talk

Earnings

Global Energy Roundup: Market Talk

25 Jul 2024, 21:59 UTC

Market Talk

Earnings

Norfolk Southern Lowers Operating Ratio in 2Q, Shares Jump -- Market Talk

25 Jul 2024, 21:51 UTC

Earnings

Update: Berkshire Is Quickly Cutting Its Stake in Bank of America. More Sales Could Be Coming. -- Barrons.com

25 Jul 2024, 21:32 UTC

Acquisitions, Mergers, Takeovers

Noble: Special Meeting of Diamond Stockholders to Vote on Transaction Is Currently Scheduled for Aug 27 >NE

25 Jul 2024, 21:32 UTC

Acquisitions, Mergers, Takeovers

Noble Corp and Diamond Offshore: Announce Expiration of Hart-Scott-Rodino Act Waiting Period and Provide Transaction Update

25 Jul 2024, 21:18 UTC

Earnings

A.J. Gallagher Earnings Show Insurance Brokers Are Anything but Humdrum -- Barrons.com

25 Jul 2024, 21:11 UTC

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

50.3% upside

12 Months Forecast

Average 27.88 USD 50.3%

High 39 USD

Low 17 USD

Based on 16 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to ACADIA Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

18.15 / 18.62Support & Resistance

Bearish events outweigh bullish events.

Bullish events outweigh bearish events.

There are no events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About ACADIA Pharmaceuticals Inc

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).